Fig. 1: Clinical outcomes, CAR-T proliferation, and peripheral blood biomarkers after donor-derived CD19 CAR-T cell infusion. | Leukemia

Fig. 1: Clinical outcomes, CAR-T proliferation, and peripheral blood biomarkers after donor-derived CD19 CAR-T cell infusion.

From: Prophylactic donor-derived CD19 CAR-T cell infusion for preventing relapse in high-risk B-ALL after allogeneic hematopoietic stem cell transplantation

Fig. 1

A Swimmer plot depicting clinical outcomes after CD19 CAR-T cell maintenance therapy. B The 2-year cumulative incidence of relapse after CD19 CAR-T cell infusion. C The probability of 2-year progression-free survival after CD19 CAR-T cell infusion. D Proliferation of CAR-T cells in patients who received a high dose (>2 × 106/kg, n = 10) and those who received a low dose (≤2 × 106/kg, n = 13) of CAR-T cells. E The peak level of serum IL-6 after CAR-T cell infusion in high dose group (n = 10) or low dose group (n = 13). F The peak level of serum CRP (c-reactive protein) after CAR-T cell infusion in high dose group (n = 10) or low dose group (n = 13). Data are represented as mean ± SEM.

Back to article page